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Bisphosphonates (BPs) are a class of drugs used to treat osteoporosis andmalignant bonemetastasis. BPs showhigh binding capacity
to the bone matrix, especially in sites of active bone metabolism. The American Society for Bone and Mineral Research defines
BRONJ as “an area of exposed bone in themaxillofacial region that has not healed within 8 weeks after identification by a healthcare
provider in a patient who is receiving or has been exposed to a bisphosphonate and has not had radiation therapy to the craniofacial
region.” Bisphosphonate-related osteonecrosis of the jaw (BRONJ) can adversely affect quality of life, as it may produce significant
morbidity.TheAmerican Association of Oral andMaxillofacial Surgeons (AAOMS) considers as vitally important that information
on BRONJ be disseminated to other dental andmedical specialties.The purpose of this work is to offer a perspective on how dentists
shouldmanage patients on BPs, to show the benefits of accurately diagnosing BRONJ, and to present diagnostic aids and treatments
strategies for the condition.
1. Introduction
Bisphosphonates (BPs) were first synthesized in 1865 in Ger-
many [1]. Since then, BPs have been widely used in industry,
in applications such as corrosion inhibition and fertilizers. As
these drugs inhibit calcium carbonate precipitation, their use
as blockers of bone resorption has been strongly advocated
[1]. BPs such as alendronate, risedronate, ibandronate, and
clodronate are used to treat several metabolic and oncologic
pathologies that promote the destruction of the skeletal
system.
BPs are divided into two main categories, that is, non-
nitrogenated and nitrogenated [2]. Examples of nonnitro-
genated BPs are etidronate and clodronate, while zoledronic
acid, pamidronate, and ibandronate are nitrogenated BPs [3].
BPs, wrongly referred to as disphosphonates in the past,
are compounds characterized by two C–P bonds. If both
bonds are located in the same carbon atom, the com-
pounds are considered germinal BPs, which are analogues
of pyrophosphate containing an atom of oxygen replacing an
atomof carbon.While hydrolysis easily dissociates pyrophos-
phates, BPs are resistant to that process.Thus, they have a long
half-life—one of the main reasons for BPs accumulation in
the bone matrix [4]. These drugs suppress osteoclast activ-
ity, reducing bone resorption and increasing bone density.
Nowadays, their main medical use is the prevention and/or
treatment of osteoporosis, osteopenia, multiple myeloma,
malignant tumor metastases to the bone, and Paget’s disease
[5].
In patients treated with oral or intravenous BPs, bisphos-
phonate-related osteonecrosis of the jaw (BRONJ) has been
and continues to be reported as a relatively rare, but poten-
tially severe complication. It is characterized clinically as an
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Table 1: Stages of BRON-J adapted from Ruggiero et al. [17].
Stage 1 Exposed bone, asymptomatic and without evidence of inflammatory, or infectious reaction in the adjacent softtissue
Stage 2 Exposed bone with associated pain, edema, and inflammation of the adjacent soft tissue and/or secondaryinfection
Stage 3
Exposed bone, with associated pain, inflammation, and infection of the adjacent soft tissue, which is hard to
manage only through oral or intravenous antibiotics therapy; the presence of extraoral skin fistula secondary to
osteonecrosis or a pathologic fracture is common among patients in this stage
area of exposed bone in the maxilla or the mandible that
has failed to heal within a period of six to eight weeks in a
patient currently or previously exposed to N-BPs who has
not undergone radiation therapy in craniofacial region [6–
8]. BRONJ progression is three-staged, which are identified
based on clinical signs and symptoms. Recently, phase zero
has been added in order to include high risk patients with no
clinical evidence of necrotic bone, but with unspecific clinical
signs and symptoms [9].
When administered orally, BPS absorption is low, in rates
equal to or below 1% of the total dose [10]. When given
intravenously, they are rapidly removed by the plasma and
show a 40% renal excretion rate in the first 24 hours, without
metabolization. While the half-life of BPs in the plasma is
short, in bone it lasts for about 10 years [11]. Different groups
of BPs may act through distinct mechanisms, but the final
results are similar, that is, sharp decreases in osteoclastic
activity and induction of apoptosis [12].
As BPs show great affinity for Ca2+ ions, mineralized
bone matrix is a natural destination for these drugs. Their
chemical structure provides resistance to enzymatic hydrol-
ysis and allows BPs to bind avidly to the surface of hydroxya-
patite crystals, creating a rapid and effective link between the
drug and bone mineral surface [13]. Once deposited on bone
surfaces, BPs promote osteoclastic apoptosis, hindering any
subsequent osteoclast-mediated bone resorption [14].
Although the full mechanism of action of BPs is poorly
understood, there are reports on their antiangiogenic prop-
erties as decreases in circulating levels of vascular endothelial
growth factor have been observed [15]. The antiangiogenic
effect of zoledronate (a 3rd generation BP) was demonstrated
in rats, supporting its use in the treatment of malignant bone
diseases, as well as in bone diseases with angiogenic com-
ponents [15]. Oral BPs are chiefly used to treat osteoporosis
and are not effective in treating malignant osteolytic lesions
[16]. BPs may cause adverse reactions and most of them
are related to the gastrointestinal system, such as nausea,
vomiting, diarrhea, esophagitis with potential progress to
esophageal ulcers; in addition, bone, muscle, and joint pain
and allergic reactions are other possible adverse effects.
2. Bisphosphonate-Related Osteonecrosis of
the Jaw (BRONJ)
A new complication of interest to the dental profession
has been recently referred to as BRONJ. It is a serious,
albeit rare adverse reaction affecting jaw bones through an
unknown mechanism, with potential to cause catastrophic
tissue destruction [18].
According to AAOMS, BRONJ is defined as “necrotic
bone exposed in maxillofacial region lasting for more than
eight weeks in BPs-treated patients who have not undergone
head and neck radiation therapy” [9].
The condition seems to be restricted to maxillomandibu-
lar complex, hence the name and the acronym BRONJ;
there are no works reporting on similar lesions elsewhere
in the body. An explanation for such fact would be the
presence of teeth [6, 7], as they render the jaws as the only
bones of the body that have an unimpeded connection with
the exterior [18, 19]. In addition, teeth may suffer from
periodontal disease, abscesses, endodontic injuries, and other
lesions, conditions that require appropriate bone metabolism
and blood supply to regain homeostasis [7]. Exposure to
intravenous BPs for the management of malignancy remains
the solemain risk factor for the development of BRONJ, as the
prevalence in such patients ranges from 0.8 to 12%. Patients
on oral BPs have a considerably lower risk to develop BRONJ
when compared to cancer patients receiving intravenous BPs
on a monthly basis. Based on data of the manufacturers
of alendronate (MERCK laboratory), the risk of BRONJ in
patients on oral treatment was calculated to be 0.7/100,000
person/year of exposure [9].
3. Staging
In 2006, Ruggiero et al. [17], supported by their experience in
diagnosing and managing 141 patients with BRONJ, imple-
mented a staging system to group patients shown in Table 1.
In patients with clinically evident BRONJ, necrotic and
infected bone is exposed to the oral environment, and
erythema and edema of the surrounding soft tissue may be
present [20]. In 25 to 40% of the cases, osteonecrosis appears
in a spontaneous manner, without relation to any particular
trauma or triggering condition [18, 19]. Spontaneous cases
may be attributed to anatomic and physiologic traits, as they
usually occur in the posterior region of the jaw where oral
mucosa is thin. This is the most affected region, followed by
the posterior maxilla, and mainly after dental extraction is
performed [18].
In spontaneous cases, the most frequent initial symptom
is an uncomfortable feeling in the mouth (paresthesia or
burning sensation), with gradual changes in the mucosa,
progressing to slow-healing ulcers. Pain may be intense and
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it is usually caused by necrotic bone infection by oral bac-
terial flora. These signs and symptoms may precede clinical
evidence of osteonecrosis and it is essential to recognize
them in order to take all possible preventive measures, since
osteonecrosis is a progressive disorder that causes extensive
exposition of jaw bones thatmay result in bone sequestra [21].
4. Diagnosis
Diagnosis is very clear, directed by anamnesis, the history of
oncologic pathology, and/or administration of BPs. Clinically
evident lesions are confirmed through conventional radio-
graphs showing radiopaque sequestrations, which are usually
round with irregular peripheral radiolucencies [22].
Radiologic and nuclear medicine imaging may be valu-
able in recognizing and defining bone lesions in patients
undergoing BPs therapy [21]. In the early phases of BRONJ,
radiographic manifestations are not detected; however, as
the disease progresses, osteonecrosis of the jaw may become
readily identifiable in X-rays. When BRONJ is established,
a poorly defined osteolytic area is seen along with cortical
destruction, loss of cancellous trabeculation, and a decrease
in bone density (similar to the radiological findings of
osteomyelitis). Early osteonecrosis restricted to small areas
of bone exposure (<1 cm) may be undetectable in panoramic
radiographs; however, signs of bone destruction arising from
this process may be recognized in computed tomography
[23]. Computed tomography (CT) may allow a greater
definition of the necrotic focuses and their relationship
with neighboring anatomic structures, making it possible to
quantify the status of bone sclerosis. However, CTmay not be
useful in staging asymptomatic patients [22].
According to Chiandussi et al. [21], scintigraphy exams
may be useful in initial assessment of BRONJ patients. In
some patients, there seemed to be a significant decrease
or even complete absence of radioisotope intake, indicating
low bone metabolism due to the absence of blood supply.
However, these imaging resources are not able to show the
difference betweenBRONJ and other causes of bone exposure
in the jaw, such as osteoradionecrosis, osteomyelitis-related
osteonecrosis of the jaw, or steroid-induced osteonecrosis
[23]. Scintigraphy (Tc99-scan) is the most sensitive diag-
nostic strategy to identify edema and vascular changes and
to locate bone necrosis even in the early stages of the dis-
ease. Nevertheless, this diagnostic technique has limitations:
Tc99-scan is unable to distinguish BRONJ from metastatic
processes [21, 24]. Biopsy of bone lesions must be carefully
evaluated because the procedure itself may damage the bone
tissue, causing a wound that may never heal properly [25].
Histological characteristics of osteonecrosis of the jaw
include necrotic bone with bacterial colonies and granulation
tissue [26] as well as decreased vascularization and number
of osteoblasts [20]. Some biopsy specimens showed fungal
and bacterial colonies. In malignancy patients treated with
BPs, such lesions occur irrespective of existence of jaw
metastases [26].
5. Risk Factors
The exact mechanism leading to BRONJ is unknown. How-
ever, risk factors to develop this conditionmay be divided into
three: risk factors related to drug intake, local risk factors,
and systemic risk factors [7]. The AAOMS, in 2009, also
mentioned anatomic traits (torus palatinus and mandibular,
the mylohyoid line), advanced age, being of Caucasian
descent, and other genetic specificities as additional risk
factors. Despite being low, the risk of developing BRONJ
increases when BP use is longer than three years, and such
time is reduced for patients on chronic corticosteroids [9].
6. Prevention
Before treatment with intravenous BPs, a patient should
undergo thorough intraoral examination followed by com-
prehensive dental treatment. In addition, optimal periodontal
health should be regained if not present. There seems to be
no contraindications for elective oral surgery in patients on
oral BPs without signs of bone exposure and less than three
years of drug usage. When the therapy is shorter than three
years and combinedwith corticosteroids, the clinician should
consider a “drug holiday” of three months before elective oral
surgery, extended to the following three months whenever
the patient’s systemic conditions allow. Such considerations
should also be taken if the use of BPs is longer than three years
regardless of concomitant use of steroids [9].
7. Treatment
To date, treatment option for patients with BRONJ is limited
and predominantly palliative, aiming at relieving the main
signs and symptoms [7]. Marx et al. [7] recommend that
treatment should eliminate and control pain, as well as
preventing progression of bone exposure through antibiotics
therapy and mouthwash with 0.12% chlorhexidine. They also
state that conservative surgical treatments are preferential,
aiming at nonexposure of necrotic bone boundaries. AAOMS
in 2009 recommended the removal of well-defined bone
sequestrations, as well as the removal and/or relining of bone
necrosis areas which are a constant source of irritation to soft
tissues [9].
Montebugnoli et al. [27] also recommended the man-
agement of osteonecrosis with nonsurgical protocol. These
authors conducted a study dividing patients into two groups,
one treated with surgery and the other treated with antibi-
otics. Data analysis showed there was no statistically signifi-
cant difference between outcomes for the two groups.
Curi et al. [28] reported on three clinical cases in which
sequestra removal was performed and autologous platelet-
rich plasma was topically applied onto the remaining defect.
After six-month follow-up, complete repair of surgical site
was seen, thus showing promising results.
Discontinuation of oral BPs in BRONJ patients has been
associated with gradual improvement of clinical disease [29].
Discontinuation for 6–12 months may result in sequestra-
tion with spontaneous resolution after surgical debridement.
Whenever systemic conditions permit, changing or stopping
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oral bisphosphonate treatment must be a result of an agree-
ment between the professionals involved and the patient [9].
8. Discussion
Intravenous BPs are usually considered stronger than those
given orally. Therefore, use of intravenous BPs is one of the
main risk factors to induce BRONJ, as evidenced by the
higher estimates of BRONJ incidence (0–10%) in patients
treated with IV drugs as compared to an oral therapy (<1%)
[30, 31].
Among the BPs, those more likely to induce BRONJ are
amino-BPs [25, 32, 33], possibly because they are stronger
than alkyl-BPs. Pamidronate, alendronate, and zoledronate
are 10, 100, and 1000 timer stronger than clodronate, respec-
tively [31]. Bone necrosis is considered dose- and time-
dependent due to the long half-life of BPs in the bone [25].
In patients who used BPs and did not experience osteone-
crosis, preventive measures should be taken, since osteone-
crosis may appear up to one decade after the start of bis-
phosphonate therapy. Patient should be advised to undergo
thorough oral examination every 3 months [34].
If osteonecrosis develops, nonsurgical management may
be beneficial and is based on antibiotic therapy. A “drug hol-
iday” may be considered in severe cases if benefits overcome
the risks of bone complications, although improvement has
not been observed to date [33, 35]. Similarly, hyperbaric oxy-
gen therapy is not effective and, therefore, not recommended
[35].
9. Conclusions
The importance of a good anamnesis and history taking
greatly helps the healthcare professional in the correct diag-
nosis of BRONJ lesions. Warning patients of the necessary
care and the potential oral manifestations, which are often
forgotten or ignored, and maintaining a professional rela-
tionship with the accompanying physician and/or oncologist
are essential for the good clinical management of patients on
BPs. All healthcare professionals should provide guidance for
patients on BPs in the sense that good oral health should be
kept by all means, since oral surgical treatment could lead
to BRONJ. For those patients using BPs but who have not
experienced BRONJ, preventive measures should be taken,
as the condition may appear up to one decade after therapy
start. Appropriate oral hygiene, along with frequent oral
examination and minimally invasive dental treatment, when
needed, are all clinical choices that must be adopted in order
to avoid BRONJ development.
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